Rebamipide Inhibits Ceramide-Induced Interleukin-8 Production in ...

Rebamipide kháng KATOIII

From Wikipedia, the free encyclopedia

Rebamipide

Clinical data
Trade names	Mucosta (JP), Rebagen (KR,CN, IN), Rebagit (RU)
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral (tablets)
ATC code	none
Identifiers
IUPAC name[show]
CAS Number	90098-04-7
PubChem CID	5042
IUPHAR/BPS	871
ChemSpider	4866
UNII	LR583V32ZR
KEGG	D01121
ChEMBL	CHEMBL1697771
Chemical and physical data
Formula	C19H15ClN2O4
Molar mass	370.786 g/mol
3D model (Jmol)	Interactive image
SMILES[show]
InChI[show]
(what is this?)  (verify)

Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2.

Rebamipide is used in a number of Asian countries including Japan (marketed as Mucosta), South Korea, China^[1] and India (where it is marketed under the trade name Rebagen). It is also approved in Russia under the brand name Rebagit.^[2] It is not approved by the Food and Drug Administration for use in the United States.

Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa, and more recently, the small intestine.^{[citation needed]} It has also been studied for the treatment of Behçet's disease.^[3] It was shown to successfully treat pouchitis in a single-N study after first-line therapies for the condition were unsuccessful.^[4] Some studies have shown effectiveness in presbyacusis (age-related hearing loss).^{[citation needed]}

It has also been shown to alleviate signs and symptoms of dry eyes in a randomised controlled trial although this is not yet widely available clinically.^[5]